Barclays
LGND icon

Barclays’s Ligand Pharmaceuticals LGND Stock Holding History

Barclays’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-160
Closed -$10K – 6329
2019
Q4 		$10K Sell
160
-1,443
-90% -$96.4K ﹤0.01% 6101
2019
Q3 		$100K Sell
1,603
-1,603
-50% -$101K ﹤0.01% 5477
2019
Q2 		$228K Buy
3,206
+1,603
+100% +$118K ﹤0.01% 4993
2019
Q1 		$126K Buy
1,603
+1,122
+233% +$85K ﹤0.01% 5182
2018
Q4 		$41K Buy
481
+321
+201% +$34.2K ﹤0.01% 5573
2018
Q3 		$27K Hold
160
– – ﹤0.01% 6355
2018
Q2 		$21K Sell
160
-802
-83% -$89.5K ﹤0.01% 6157
2018
Q1 		$99K Buy
+962
New +$95.1K ﹤0.01% 5388
2017
Q4 		– Sell
-321
Closed -$27K – 7016
2017
Q3 		$27K Hold
321
– – ﹤0.01% 5664
2017
Q2 		$24K Buy
+321
New +$22.5K ﹤0.01% 5705
2014
Q4 		– Sell
-43,762
Closed -$1.26M – 7453
2014
Q3 		$1.26M Buy
+43,762
New +$1.45M ﹤0.01% 3097
2014
Q2 		– Sell
-272,189
Closed -$11.4M – 7710
2014
Q1 		$11.4M Buy
272,189
+80,150
+42% +$3.34M 0.01% 1054
2013
Q4 		$6.23M Buy
+192,039
New +$6.26M 0.01% 1632

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Barclays's LGND Position: Q1 2026 in Review

Barclays reduced its Ligand Pharmaceuticals (LGND) stake by 82% in Q1 2026, selling an estimated $5.34M and leaving 6,008 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2643.

Barclays first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $39.7M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Barclays held 6,008 shares of Ligand Pharmaceuticals worth $1.2M as of Q1 2026.
  • Barclays sold 26,974 Ligand Pharmaceuticals shares in Q1 2026, an estimated $5.34M.
  • Ligand Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2643 holding.
  • Barclays first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Ligand Pharmaceuticals position peaked at $39.7M in Q3 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.